Paper8101302
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.
Pape JW and 4 others. Lancet, 1993. Cited by 409 papers, by iCite.
Cite this record
ConductScience Library. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Papers, record 8101302. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8101302
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| AIDS-Related Opportunistic Infections | Major topic |
| HIV Seropositivity | Major topic |
| Isoniazid | Major topic |
| Tuberculosis, Pulmonary | Major topic |
| Acquired Immunodeficiency Syndrome | |
| Adult | |
| Drug Therapy, Combination | |
| Female | |
| HIV Infections | |
| Humans | |
| Male | |
| Middle Aged | |
| Pyridoxine | |
| Treatment Outcome |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R21AI 33877 | NIAID NIH HHS | United States | R21AI033877 | PubMed and NIH | NIH RePORTER |
| R37 AI 22624 | NIAID NIH HHS | United States | R37AI022624 | PubMed and NIH | NIH RePORTER |
| TW00018 | FIC NIH HHS | United States | PubMed | PubMed |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 8103158 | Tuberculosis and HIV infection. | https://conductscience.org/library/papers/8103158 | PubMed |
| Comment in | 8103159 | Tuberculosis and HIV infection. | https://conductscience.org/library/papers/8103159 | PubMed |
Cited by108
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 409 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42373911 | Breaking barriers: Implementation of a tuberculosis preventive treatment protocol among newly eligible populations with promising results. | Eur J Clin Microbiol Infect Dis | 2026 | https://conductscience.org/library/papers/42373911 | PubMed |
| 41029364 | Between Process Gaps, Knowledge, and Patient Trust: Healthcare Workers' Insights on Implementing Tuberculosis Preventive Therapy for People with HIV in the Philippines and Indonesia. | Implement Sci Commun | 2025 | https://conductscience.org/library/papers/41029364 | PubMed |
| 39810035 | Electronic structure modulation of ultrathin PtRuMoCoNi high-entropy alloy nanowires for boosting peroxidase-like activity and sensitive colorimetric determination of isoniazid and hydrazine. | Mikrochim Acta | 2025 | https://conductscience.org/library/papers/39810035 | PubMed |
| 39345793 | People Living With HIV Have More Intact HIV DNA in Circulating CD4+ T Cells if They Have History of Pulmonary Tuberculosis. | Pathog Immun | 2024 | https://conductscience.org/library/papers/39345793 | PubMed |
| 37143101 | Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials. | Arch Public Health | 2023 | https://conductscience.org/library/papers/37143101 | PubMed |
| 35486953 | The Impact of Vitamin A Deficiency on Tuberculosis Progression. | Clin Infect Dis | 2022 | https://conductscience.org/library/papers/35486953 | PubMed |
| 35071602 | Analysis of the Research Hotspot of Drug Treatment of Tuberculosis: A Bibliometric Based on the Top 50 Cited Literatures. | Biomed Res Int | 2022 | https://conductscience.org/library/papers/35071602 | PubMed |
| 34903214 | Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis. | BMC Med | 2021 | https://conductscience.org/library/papers/34903214 | PubMed |
| 34520459 | Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. | PLoS Med | 2021 | https://conductscience.org/library/papers/34520459 | PubMed |
| 34308207 | Implementation of Isoniazid Preventive Therapy Among HIV-Infected Children at Health Facilities in Nairobi County, Kenya: A Cross-Sectional Study. | East Afr Health Res J | 2019 | https://conductscience.org/library/papers/34308207 | PubMed |
| 34255776 | Impact of Isoniazid Preventive Therapy on Tuberculosis incidence among people living with HIV: A secondary data analysis using Inverse Probability Weighting of individuals attending HIV care and treatment clinics in Tanzania. | PLoS One | 2021 | https://conductscience.org/library/papers/34255776 | PubMed |
| 32773999 | Implementation of Isoniazid Preventive Therapy among People Living with HIV in Northwestern Nigeria: Completion Rate and Predictive Factors. | J Glob Infect Dis | 2020 | https://conductscience.org/library/papers/32773999 | PubMed |
| 32417884 | Enhanced Human Immunodeficiency Virus-1 Replication in CD4+ T Cells Derived From Individuals With Latent Mycobacterium tuberculosis Infection. | J Infect Dis | 2020 | https://conductscience.org/library/papers/32417884 | PubMed |
| 32411454 | Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study. | AIDS Res Treat | 2020 | https://conductscience.org/library/papers/32411454 | PubMed |
| 32053584 | Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. | MMWR Recomm Rep | 2020 | https://conductscience.org/library/papers/32053584 | PubMed |
| 31688742 | Factors Associated With Latent Tuberculosis Infection Treatment Failure Among Patients With Commercial Health Insurance-United States, 2005-2016. | J Public Health Manag Pract | 2021 | https://conductscience.org/library/papers/31688742 | PubMed |
| 31364692 | Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. | Am J Epidemiol | 2019 | https://conductscience.org/library/papers/31364692 | PubMed |
| 30896131 | Fifty Years of Supporting Global Health Research at the NIH Fogarty International Center. | Ann Glob Health | 2019 | https://conductscience.org/library/papers/30896131 | PubMed |
| 30885144 | Epidemiology and outcome of HIV patients in Finland co-infected with tuberculosis 1998-2015. | BMC Infect Dis | 2019 | https://conductscience.org/library/papers/30885144 | PubMed |
| 29770360 | Biomarkers Associated with Death After Initiating Treatment for Tuberculosis and HIV in Patients with Very Low CD4 Cells. | Pathog Immun | 2018 | https://conductscience.org/library/papers/29770360 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8101302
GET https://conductscience.org/api/papers/v1/8101302/cited_by?page=2